The Lancet Oncology in conversation with
Celková doba trvání:
12 h 54 min
Richard Bryant on transperineal vs transrectal biopsy for prostate cancer
The Lancet Oncology in conversation with
18:02
Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)
The Lancet Oncology in conversation with
07:33
Ariana Znaor on cancer surveillance in the Eastern Mediterranean region
The Lancet Oncology in conversation with
20:03
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials
The Lancet Oncology in conversation with
18:03
Yannick Romero on the changing landscape of national cancer control plans
The Lancet Oncology in conversation with
24:40
M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries
The Lancet Oncology in conversation with
22:15
Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma
The Lancet Oncology in conversation with
15:07
Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination
The Lancet Oncology in conversation with
17:21
May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics
The Lancet Oncology in conversation with
40:45
Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)
The Lancet Oncology in conversation with
13:22
Emmy Boerrigter on dose selection of novel anticancer drugs
The Lancet Oncology in conversation with
11:41
Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations
The Lancet Oncology in conversation with
36:56
Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment
The Lancet Oncology in conversation with
24:08
James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean
The Lancet Oncology in conversation with
35:05
Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials
The Lancet Oncology in conversation with
11:22
Maria Kyrgiou on innovations in gynaecological cancers and global disparities
The Lancet Oncology in conversation with
25:42
Georgios Lyratzopoulos on the use of chemotherapy and radiotherapy in patients with eight common cancers
The Lancet Oncology in conversation with
34:43
Mike Sathekge on radioligand therapy of metastatic castration-resistant prostate cancer
The Lancet Oncology in conversation with
16:06
Shankar Siva on stereotactic body radiotherapy for primary renal cell carcinoma
The Lancet Oncology in conversation with
13:53
Neerja Bhatla on a new quadrivalent HPV vaccine
The Lancet Oncology in conversation with
12:24
Chandra Are on the Lancet Oncology Commission on Global Cancer Surgery
The Lancet Oncology in conversation with
43:49
Philipp Karschnia on tissue sampling and processing during resection of diffuse intracranial glioma
The Lancet Oncology in conversation with
17:10
Wanda Cui on measuring ovarian toxicity
The Lancet Oncology in conversation with
10:37
Ticiana Leal on Tumour Treating Fields
The Lancet Oncology in conversation with
09:01
Xuesong Han on cancer diagnosis during the COVID-19 pandemic in the USA
The Lancet Oncology in conversation with
12:31
Carlos Fernández de Larrea and Damian Green on BCMA CAR T cells in multiple myeloma
The Lancet Oncology in conversation with
33:50
Madeline Pe on the SISAQOL initiative
The Lancet Oncology in conversation with
14:01
Kadia Petricca and Joyce Kambugu on access to essential cancer medicines for children
The Lancet Oncology in conversation with
28:40
Mark Lythgoe on UK oncology drug approval after Brexit
The Lancet Oncology in conversation with
14:11
Janet Brown on the phase 2/3 STAR trial
The Lancet Oncology in conversation with
20:43
Valerie Speirs on biomarkers in male breast cancer
The Lancet Oncology in conversation with
17:40
Sameer Bakhshi on sex disparities in childhood cancer in India
The Lancet Oncology in conversation with
23:02
Shankar Siva on radiotherapy for primary renal cell carcinoma
The Lancet Oncology in conversation with
08:30
Mark Lawler and Richard Sullivan on the European Groundshot
The Lancet Oncology in conversation with
23:20
Samar Alhomoud on challenges for cancer control in the Gulf region
The Lancet Oncology in conversation with
11:27
Inge Marie Svane on mRNA vaccines for cancer treatment
The Lancet Oncology in conversation with
08:11
Eline Giraud and Elise Smolders on QT interval prolongation potential of anticancer
The Lancet Oncology in conversation with
11:39
Ignace Vergote and Maria Kyrgiou on gynaecological cancers
The Lancet Oncology in conversation with
10:30
David J Pinato on SARS-CoV-2 omicron outcomes among patients with cancer
The Lancet Oncology in conversation with
05:19
Wilfred Ngwa, Beatrice Wiafe-Addai, and David Kerr on cancer in sub-Saharan Africa
The Lancet Oncology in conversation with
30:55
